Abstract
Escherichia coli is an important cause of neonatal sepsis and the third most prevalent cause of neonatal infection in sub-Saharan Africa, often with negative outcomes. Development of maternally administered vaccines is under consideration, but to provide adequate protection, an understanding of serotypes causing invasive disease in this population is essential. We describe the genomic characteristics of a collection of neonatal E. coli isolates from a tertiary hospital in Blantyre, Malawi, with specific reference to potential protection by vaccines under development. Neonatal blood or cerebrospinal fluid cultures from 2012-2021 identified 205 E. coli isolates, and 170 could be recovered for sequencing. There was very high diversity in sequence types, LPS O-antigen-type and fimbrial H-type, which all showed temporal fluctuations and previously undescribed diversity, including ten putative novel O-types. Vaccines in clinical trials target the O-antigen but would only protect against one third (33.7%) of neonatal sepsis cases in this population (EXPEC9V, in clinical trials). An O-antigen based vaccine would require 30 different O-types to protect against 80% of infections. Vaccines against neonatal sepsis in Africa are of considerable potential value, but their development requires larger studies to establish the diversity and stability over time of relevant O-types for this population.
Data summary All sequencing data is freely available under the sequencing project IDs ERP120687 (short read data; accessions in Supplementary Table 1) and PRJNA1121524 (long-read data; accessions in Supplementary Table 2), detailed per-isolate information is provided in Supplementary Table 3. Blood culture and CSF data used to show the trends and numbers of E. coli cases per year is available in Supplementary Table 4.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was conducted with funding from the Bill & Melinda Gates Foundation (project grant number INV-005692 to NAF) and Wellcome core institutional grants for MLW (206545/Z/17/Z) and the Wellcome Sanger Institute (220540/Z/20/A). EH acknowledges funding from the BBSRC (BB/V011278/1, BB/V011278/2). For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was ethically approved by the Kamuzu University of Health Sciences College of Medicine Research Ethics Committee (COMREC P.06.20.3071). The ID numbers used in this manuscript are specimen IDs generated by the MLW diagnostic laboratory and not patient IDs; only the research team and members of the clinical staff in hospital that have access to the password protected laboratory information management system at MLW would be able to make the link to an individual.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All sequencing data is freely available under the sequencing project IDs ERP120687 (short read data; accessions in Supplementary Table 1) and PRJNA1121524 (long-read data; accessions in Supplementary Table 2), detailed per-isolate information is provided in Supplementary Table 3. Blood culture and CSF data used to show the trends and numbers of E. coli cases per year is available in Supplementary Table 4.
